Case report: Iliopsoas hematoma during the clinical course of severe COVID-19 in two male patients

27Citations
Citations of this article
78Readers
Mendeley users who have this article in their library.

Abstract

Anticoagulation plays a major role in reducing the risk of systematic thrombosis in patients with severe COVID-19. Serious hemorrhagic complications, such as intracranial hemorrhage, have also been recognized. However, intra-abdominal hemorrhage is under-recognized because of its rare occurrence, despite high mortality. Here, we discuss two cases of spontaneous iliopsoas hematoma (IPH) likely caused by anticoagulants during the clinical course of COVID-19. We also explored published case reports to identify clinical characteristics of IPH in COVID-19 patients. The use of anticoagulants may increase the risk of lethal IPH among COVID-19 patients becsuse of scarce data on optimal dosage and adequate monitoring of anticoagulant effects. Rapid diagnosis and timely intervention are crucial to ensure good patient outcomes.

Cite

CITATION STYLE

APA

Nakamura, H., Ouchi, G., Miyagi, K., Higure, Y., Otsuki, M., Nishiyama, N., … Fujita, J. (2021). Case report: Iliopsoas hematoma during the clinical course of severe COVID-19 in two male patients. American Journal of Tropical Medicine and Hygiene, 104(3), 1018–1021. https://doi.org/10.4269/ajtmh.20-1507

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free